Disclaimer - Important

These materials are not directed at or intended to be accessed by persons located outside India. these materials are being made available on this website to comply with securities and exchange board of india (issue of capital and disclosure requirements) regulations, 2018, as amended.

IMPORTANT : You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the Draft Red Herring Prospectus of Entero Healthcare Solutions Limited (the “Company”) dated September 13 - 2023 (the “Draft Red Herring Prospectus”) filed with the Securities and Exchange Board of India (“SEBI”), BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”, and together with BSE, the “Stock Exchanges”) and hosted on this website. In accessing the Draft Red Herring Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.

The Draft Red Herring Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Draft Red Herring Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. No part of the contents of the Draft Red Herring Prospectus shall be copied or duplicated in any form by any means, or redistributed.

The Draft Red Herring Prospectus has been hosted on this website as prescribed under Regulation 26(1) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”). You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neither the Company nor any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.

The Draft Red Herring Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction and is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company or any of its affiliates would by virtue of such distribution become subject to new or additional registration, licensing or other regulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (a) within the United States solely to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act, and (b) outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made.

Any person into whose possession the Draft Red Herring Prospectus comes is required to inform himself or herself about and to observe any such restrictions. Neither the Company nor any of its affiliates is soliciting any action based on the Draft Red Herring Prospectus, and it should not be construed as an offer to sell or the solicitation of an offer to buy any securities. Potential investors should not rely on the Draft Red Herring Prospectus for any investment decision. Any potential investor should note that investment in the securities involves a high degree of risk. For details, potential investors should refer to the red herring prospectus, including the section titled “Risk Factors”, when available.

Neither the Company nor any of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Company and its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Draft Red Herring Prospectus beyond the date of the Draft Red Herring Prospectus. The Company and its affiliates will not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company, any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.

If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access you are located in India. If you cannot make this confirmation, you must press the button marked "I Do Not Confirm".

The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.



I Confirm I Do Not Confirm

Disclaimer - Important

THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA.

IMPORTANT : You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the Red Herring Prospectus of Entero Healthcare Solutions Limited (the “Company”) dated February 5, 2024 (the “Red Herring Prospectus”) filed with the Registrar of Companies, Delhi and Haryana at New Delhi and thereafter with the Securities and Exchange Board of India (“SEBI”) and the BSE Limited and the National Stock Exchange of India Limited, in relation to the initial public offering of the equity shares of face value of ₹ 10 each (“Equity Shares”) of the Company (“Offer”).

THE RED HERRING PROSPECTUS IS BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (“SEBI ICDR REGULATIONS”). You are advised to read this disclaimer carefully before reading, accessing or making any other use of the Red Herring Prospectus. In accessing the Red Herring Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.

The Red Herring Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Red Herring Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. No part of the contents of the Red Herring Prospectus shall be copied or duplicated in any form by any means, or redistributed. The information contained in the Red Herring Prospectus may not be updated since its original publication date and may not reflect the latest updates.

The Red Herring Prospectus has been hosted on this website as prescribed under Regulation 26 of the SEBI ICDR Regulations. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neither the Company nor any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.

The Red Herring Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction and is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company or any of its affiliates would by virtue of such distribution become subject to new or additional registration, licensing or other regulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold (i) outside of the United States in “offshore transactions” as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) to “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act. No person outside India is eligible to bid for Equity Shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which comprises the Red Herring Prospectus and the preliminary international wrap (which contains, among other things, the selling restrictions for the Offer outside India).

Any person into whose possession the Red Herring Prospectus comes is required to inform himself or herself about and to observe any such restrictions.

Neither the Company nor any of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Company and its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Red Herring Prospectus beyond the date of the Red Herring Prospectus. The information in the Red Herring Prospectus is as of the date thereof and neither the Company nor its affiliates, directors or employees are under any obligation to update or revise the Red Herring Prospectus to reflect circumstances arising after the date thereof.

Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see the section titled “Risk Factors” in the Red Herring Prospectus. Any decision on whether to invest in the equity shares described in the red herring prospectus of the Company dated February 5, 2024 (“RHP”), must be made solely on the basis of the RHP. As there may be material changes in the draft red herring prospectus dated September 13, 2023 (the “DRHP”) versus the RHP, potential investors should not have relied on the DRHP.

The Company and its affiliates will not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company, any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.

If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access you are located in India. If you cannot make this confirmation, you must press the button marked "I Do Not Confirm". The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.



I Confirm I Do Not Confirm

Disclaimer - Important

THESE MATERIALS ARE NOT DIRECTED AT OR INTENDED TO BE ACCESSED BY PERSONS LOCATED OUTSIDE INDIA.

IMPORTANT : You must read and agree with the terms and conditions of the following disclaimer before continuing.

The following disclaimer applies to the Prospectus of Entero Healthcare Solutions Limited (the “Company”) dated February 13, 2024 (the “Prospectus”) filed with the Registrar of Companies, Delhi and Haryana at New Delhi and thereafter with the Securities and Exchange Board of India (“SEBI”) and the BSE Limited and the National Stock Exchange of India Limited, in relation to the initial public offering of the equity shares of face value of ₹ 10 each (“Equity Shares”) of the Company (“Offer”).

THE PROSPECTUS IS BEING MADE AVAILABLE ON THIS WEBSITE TO COMPLY WITH SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED (“SEBI ICDR REGULATIONS”). You are advised to read this disclaimer carefully before reading, accessing or making any other use of the Prospectus. In accessing the Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them from time to time.

The Prospectus is directed at, and is intended for distribution to, and use by, residents of India only. The information in this portion of our website, including the Prospectus, is not for publication or distribution, directly or indirectly, in or into the United States. No part of the contents of the Prospectus shall be copied or duplicated in any form by any means, or redistributed.

The Prospectus has been hosted on this website as prescribed under Regulation 26 of the SEBI ICDR Regulations. You are reminded that documents transmitted in electronic form may be altered or changed during the process of transmission and consequently, neither the Company nor any of its affiliates accepts any liability or responsibility whatsoever in respect of alterations or changes which have taken place during the course of transmission of electronic data.

The Prospectus does not constitute an offer to sell or an invitation to subscribe to the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer or invitation in such jurisdiction and is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where (a) distribution or use of such information would be contrary to law or regulation; or (b) the Company or any of its affiliates would by virtue of such distribution become subject to new or additional registration, licensing or other regulatory requirements. The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, such Equity Shares are being offered and sold (i) outside of the United States in “offshore transactions” as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur; and (ii) to “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) pursuant to Section 4(a) of the U.S. Securities Act. No person outside India is eligible to bid for Equity Shares in the Offer unless that person has received the preliminary offering memorandum for the Offer, which comprises the red herring prospectus dated February 5, 2024 and the preliminary international wrap (which contains, among other things, the selling restrictions for the Offer outside India).

Any person into whose possession the Prospectus comes is required to inform himself or herself about and to observe any such restrictions.

Neither the Company nor any of its affiliates will be responsible for any loss or damage that could result from interception and interpretation by any third parties of any information being made available to you through this website. The Company and its affiliates cannot and do not guarantee the accuracy, timeliness or completeness of the information being made available to you in the Prospectus beyond the date of the Prospectus. The information in the Prospectus is as of the date thereof and neither the Company nor its affiliates, directors or employees are under any obligation to update or revise the Prospectus to reflect circumstances arising after the date thereof.

Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see the section titled “Risk Factors” of the Prospectus.

The Company and its affiliates will not be responsible for any loss to any person or entity caused by any shortcoming, defect or inaccuracy which may have inadvertently or otherwise crept into the website. Neither the Company, any of its affiliates nor their directors, officers and employees will be liable or have any responsibility of any kind for any loss or damage that you incur in the event of any failure or disruption of this website, or resulting from the act or omission of any other party involved in making this website or the data contained therein available to you, or from any other cause relating to your access to, inability to access, or use of the website or these materials.

If you are not permitted to view the materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

To access this information, you must confirm by pressing on the button marked "I Confirm" that, at the time of access you are located in India. If you cannot make this confirmation, you must press the button marked "I Do Not Confirm".

The documentation contained in these pages is posted solely to comply with Indian legal and regulatory requirements. Making the information contained herein available in electronic format does not constitute an offer to sell, the solicitation of an offer to buy, or a recommendation to buy or sell securities of the Company in the United States or in any other jurisdiction, including without limitation, India.



I Confirm I Do Not Confirm

Prabhat Agrawal
Managing Director, Chief Executive Officer & Co-Founder
Prem Sethi
Whole Time Director, Chief Operating Officer & Co-Founder

Our Key Managerial Personnel and Senior Management collectively have 85+ years of work experience in pharmaceutical marketing
healthcare supply chain, consumer and other sectors.

Balakrishnan Natesan Kaushik
Group Chief Financial Officer
Sambit Mohanty
PRESIDENT - INSTITUTION BUSINESS
Abhitesh Kumar
President - Retail Business & New Initiatives
Sanu Kapoor
Vice President - Legal and General Counsel, Company Secretary and Compliance Officer
Prabhat Agrawal
MANAGING DIRECTOR, CHIEF EXECUTIVE OFFICER & CO-FOUNDER

Prabhat Agrawal is the Promoter, Managing Director and Chief Executive Officer of our Company and he is currently responsible for the overall business strategy, operations, financial performance and management of our Company. He obtained his bachelor’s degree in commerce from Mumbai University and a master’s degree in management from The Indian School of Business, Hyderabad. He is also a qualified Chartered Accountant with the Institute of Chartered Accountants of India and is a Chartered Financial Analyst with the Institute of Chartered Financial Analysts, USA.

He has more than 20 years of experience. Prior to joining our Company, he was associated as Chief Executive Officer with Alkem Laboratories Limited, as Group CFO with Metalfrio Solutions SA, Brazil, as Deputy Operations Director with Frigoglass Industries Nigeria Limited, as member of Corporate Strategy and Business Development Cell with Aditya Birla Management Corporation Limited and other organizations in various managerial roles. He received the “CEO Of the Year – 2016” award at the 9th Annual Pharmaceutical Leadership Summit and Pharma Leaders Business Leadership Awards 2016.

Prem Sethi
WHOLE TIME DIRECTOR, CHIEF OPERATING OFFICER & CO-FOUNDER

Prem Sethi is the Promoter, Whole-time Director and Chief Operating Officer of our Company. He obtained his bachelor’s degree in pharmacy from Rajiv Gandhi University of Health Sciences, Karnataka and a master’s diploma in Clinical Research and Pharmacovigilance from James Lind Institute, Karnataka. He has more than 16 years of experience.

Prior to joining our Company, he was associated as Director – Offering Development and Product Management with IQVIA Consulting and Information Services India Private Limited, as Senior Practice Leader with Excellence Data Research Private Limited, as Manager with WNS Global Services Private Limited, and as Business Analyst with Evalueserve Private Limited. He is currently responsible for development and product management in our Company. He received the Business Leader Award from Business Transformation Awards 2021 by Mint and Techcircle.

Balakrishnan Natesan Kaushik
GROUP CHIEF FINANCIAL OFFICER

Balakrishnan Natesan Kaushik (“Bala”) is the Group Chief Financial Officer of our Company. Bala holds a bachelor’s degree in commerce from the University of Mumbai and is a qualified Chartered Accountant.

Bala has around 25 years of post-qualification experience in Finance entailing Strategic Planning & Budgeting, Business Restructuring, Costing & Pricing, Working capital Management, Controlling, Financial & Management Accounting, Compliance, Audits & Due Diligence across diverse industries at plant and corporate level. He has multi-cultural/ cross continental exposure having worked with Deloitte, Saint Gobain, Quantum Advisors, Piramal Healthcare, Sandoz, IMS Health and Nestle Skin Health both in India and abroad.

He is currently responsible for strategic finance, investor relations, planning, financial reporting, treasury, compliance and controls. He has been associated with our Company since June 6, 2018.

Jayant Prakash
GENERAL COUNSEL, COMPANY SECRETARY & COMPLIANCE OFFICER

Jayant Prakash is the Vice President - General Counsel, Company Secretary and Compliance Officer of our Company. He obtained a bachelor’s degree in corporate secretaryship from Pondicherry University, a bachelor’s degree in law from Delhi University and a master’s degree in business administration from the Institute of Chartered Financial Analysts of India University, Tripura. He also holds an advanced diploma in computer integrated management (finance and accounts) from First Computers, Patna and is fellow member of the Institute of Company Secretaries of India. He has more than 18 years of experience. Prior to joining our Company, he was associated as Director Legal & Secretarial with Emcure Pharmaceuticals Limited, as Compliance Officer, Company Secretary and Head of Legal with Metropolis Healthcare Limited, as Chief Manager with L&T Financial Services Limited, as Vice President – Company Secretary and Compliance Officer with Elara Capital (India) Private Limited, as Vice President – Legal and Secretarial with Sushil Financial Services Private Limited, as AVP Compliance with Vivro Financial Services Private Limited, as Company Secretary with Fact Enterprise Limited, as Company Secretary with Chemicals International Limited and as Assistant Company Secretary with Machino Plastics Limited. He is currently responsible for legal, secretarial, compliance, M&A and legal strategic advisory in our Company. He has been associated with our Company since November 1, 2021.

Sambit Mohanty
PRESIDENT - INSTITUTION BUSINESS

Sambit Mohanty is the President - Institutional Business of our Company. He obtained his bachelor’s of science from Utkal University and master’s diploma in Business Finance (PGDBF) from Indian Institute of Finance, New Delhi. He has more than 24 years of experience. Prior to joining our Company, he was associated as General Manager with Alkem Laboratories Limited, as Business Head with Glenmark Pharmaceuticals Limited, as Senior Manager Business Operation with Abbott Truecare Pharma Private Limited, as Area Business Manager with Orchid Healthcare and as Business Manager with Vision Enterprise and Emcure Pharmaceuticals Limited. He is currently responsible for Business Development, Sales and Marketing and Key Accounts in our Company. He has been associated with our Company since May 1, 2018.

Shashwat Nigam
VICE PRESIDENT - HEAD RETAIL PHARMA BUSINESS

Shashwat Nigam is the Vice President - Head Retail Pharma Business of our Company. He obtained his bachelor’s degree of Technology in Mechanical Engineering from Banaras Hindu University, Varanasi and completed a post graduate program in business management from The Indian School of Business, Hyderabad. He has more than 16 years of experience. Prior to joining our Company, he was associated as Chief Business Officer with ImmaculateBites Private Limited, as COO – Indepot with Home Interior Designs E – Commerce Private Limited and Hindustan Unilever Limited. He is currently responsible for retail pharma business, business development, supply chain management, and business operation in our Company. He has been associated with our Company since July 10, 2023.

ABHITESH KUMAR
President - Retail Business & New Initiatives

Abhitesh Kumar is heading Retail Pharma business for Entero. Abhitesh has over 10 years of post-qualification experience in P&L management, Strategic planning, General management, Business operations, corporate strategy & financial planning, . He has multi industry experience having worked in Retail, Healthcare, Pharmaceutical and financial services industry.

During his previous stint at Fortis Healthworld, As a General Manager, he was responsible for Business operations and store level profitability and played instrumental role in turning around profitability of multiple regions.

Abhitesh holds an M.B.A from the Indian Institute of Management, Calcutta and an Engineering degree (B.E) from BITS Pilani.

Sanu Kapoor
Vice President - Legal and General Counsel, Company Secretary and Compliance Officer

Ms. Sanu Kapoor is an associate member of the Institute of Company Secretaries of India (ACS) and the Institute of Cost and Management Accountants of India (ACMA). She is a graduate of Law and Commerce from Mumbai University and holds an EMBA degree from NMIMS, Mumbai.

She is a seasoned Governance and Legal Professional with over two decades of experience spanning diverse sectors, including retail, civil aviation, heavy engineering (elevators), advertising and media, pharmaceuticals, and construction. Before joining her current company, she held key roles with leading Indian conglomerates and multinational corporations, such as Tata Motors' associate, Automobile Corporation of Goa Ltd, Praxis Home Retail Ltd, Otis Elevator (I) Ltd, Publicis Groupe, Go Airlines, UniChem Laboratories, and Pepe Jeans London.

With a proven track record in managing complex projects, including mergers and acquisitions, she has been instrumental in driving strategic legal initiatives, ensuring regulatory compliance, and strengthening governance frameworks. As a key member of the Leadership Team, she has worked in close collaboration with the Board of Directors.

Her expertise spans corporate governance, the development and implementation of the best corporate policies and codes of conduct, and leadership in key areas such as contract management, litigation oversight, investigations, and intellectual property matters.